RFK Jr. and the HHS will no longer recommend annual COVID-19 vaccines for healthy pregnant women and young adults, according to a video announcement posted on X May 27 by Secretary of Health and Human Services Robert F. Kennedy Jr. A few days later, the CDC took a slightly different stance and stated that children between the ages of 6 months and 17 years may get the COVID-19 vaccine through shared decision-making between parents and healthcare providers. The CDC also updated the adult immunization schedule to say there is “no guidance” on use for pregnancy. These decisions have sparked much debate among public health experts, policymakers and government officials. Here are the pros and cons of such a policy shift.
As Kennedy cited in his video announcement, the U.S. seems to be aligning its vaccine policy with other countries such as the U.K. and Australia that have stopped recommending routine COVID-19 vaccines for young healthy adults. In addition, according to the new recommendations, the focus of vaccinations will largely be on high-risk populations, namely those who are 65 years of age and older as well as younger individuals with at least one medical condition that puts them at high risk for COVID-19. This could allow resources and attention to be redirected to the populations that need the vaccine most.
The new recommendations also demand evidence in answering important questions the public deserves to know. For younger healthy American adults, getting approval for the vaccine will require placebo-controlled trials to show a benefit for that particular population. As an example, does a healthy 31-year-old male with no medical problems need to get a COVID-19 booster every single year, even after having received several COVID-19 boosters in the past? These are the types of questions that all Americans would like to and deserve to know with respect to COVID vaccinations.
On the flip side, the new recommendations have many public health experts concerned. Pregnant healthy females could be barred from getting the COVID-19 vaccine, since the CDC has failed to provide guidance on the issue. Without a strong recommendation from the CDC, many pregnant patients could face real barriers from insurance companies to cover the vaccine, according to The New York Times.
Pregnant women are at high risk for COVID infection and complications because pregnancy results in a weakened immune system. As Dr. Steven Fleischman, President of the American College of Obstetricians and Gynecologists states, “The science has not changed. It is very clear that COVID infection during pregnancy can be catastrophic and lead to major disability.”
The new recommendations could harm vulnerable populations. In addition to potential decreased vaccination rates and adverse outcomes for pregnant females, children could also suffer. When pregnant females get vaccinated against COVID-19 in the third trimester, they are able to pass along antibodies and protection to their infants, who have not developed mature immune systems. If pregnant females do not get vaccinated, infants will lack these antibodies and could then go on to develop severe complications from the virus should they get infected.
Finally, the new recommendations could limit access to the vaccine to those that want it. Private insurance companies usually require FDA approval and CDC recommendations to cover the vaccine as part of health insurance. The current CDC recommendations simply state young children may get the vaccine with shared-decision making, not outright stating that they should get the vaccine. In addition, the CDC falls short in explicitly recommending the vaccine for pregnant females. This could prevent private insurance companies from fully covering the vaccine. Ultimately, this may mean some pregnant women and those that cannot afford the vaccine may not have access to it.
The new recommendations for the COVID-19 vaccine for children and pregnant females was made without the customary use of independent advisors, and could have important implications for public health. While aligning with international practices, the move could significantly limit the amount of vaccines available for millions of Americans.
